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Avian influenza A of the subtype H7N9 has been responsible for almost 1,600 confirmed 
human infections and more than 600 deaths since its first outbreak in 2013. Although 
sustained human-to-human transmission has not been reported yet, further adaptations 
to humans in the viral genome could potentially lead to an influenza pandemic, which may 
have severe consequences due to the absence of pre-existent immunity to this strain at 
population level. Currently there is no influenza A (H7N9) vaccine available. Therefore, 
in case of a pandemic outbreak, alternative preventive approaches are needed, ideally 
even independent of the type of influenza virus outbreak. Bacillus Calmette–Guérin 
(BCG) is known to induce strong heterologous immunological effects, and it has been 
shown that BCG protects against non-related infection challenges in several mouse 
models. BCG immunization of mice as well as human induces trained innate immune 
responses, resulting in increased cytokine responses upon subsequent ex vivo periph-
eral blood mononuclear cell restimulation. We investigated whether BCG (Statens Serum 
Institut-Denmark)-induced trained immunity may protect against a lethal avian influenza 
A/Anhui/1/2013 (H7N9) challenge. Here, we show that isolated splenocytes as well as 
peritoneal macrophages of BCG-immunized BALB/c mice displayed a trained immunity 
phenotype resulting in increased innate cytokine responses upon ex vivo restimulation. 
However, after H7N9 infection, no significant differences were found between the BCG 
immunized and the vehicle control group at the level of survival, weight loss, pulmonary 
influenza A nucleoprotein staining, or histopathology. In conclusion, BCG-induced trained 
immunity did not result in protection in an oseltamivir-sensitive influenza A/Anhui/1/2013 
(H7N9) challenge mouse model.
Keywords: avian influenza a/anhui/1/2013 (h7n9), bacillus calmette–guérin, trained immunity, innate immune 
memory, oseltamivir
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inTrODUcTiOn
Since its first outbreak in China in 2013 until December 2017, 
avian influenza A (H7N9) has been responsible for 1,565 con-
firmed human cases, including 612 deaths (1). Infections are 
characterized by a high incidence of pneumonia, respiratory fail-
ure, and acute respiratory distress syndrome. Avian influenza A 
(H7N9) is transmitted after contact with live poultry or exposure 
to contaminated environments. Apart from some small reported 
clusters, sustained human-to-human transmission is rare (2). 
Nevertheless, because immunity to this strain at population level 
is negligible, public authorities fear that possible additional muta-
tions and reassortment with circulating other human-adapted 
influenza viruses may enable human–human transmission and 
infection, which could potentially lead to a severe H7N9 influ-
enza pandemic (3).
Vaccine development is part of pandemic preparedness stra-
tegies. Although numerous inactivated and live attenuated H7 vac-
cines are being developed, the immunogenicity of non-adjuvanted 
or aluminum hydroxide-adjuvanted candidate H7 vaccines is low 
(4, 5). Therefore, novel approaches for protection against influenza 
A (H7N9) are needed. Adjuvanted (MF59 or AS03) vaccines have 
shown to elicit enhanced immunogenicity against H7N9 (6–8). 
An alternative approach is to make use of non-specific benefi- 
cial effects of already existing vaccines, via the induction of the 
newly described process of trained immunity. Bacillus Calmette–
Guérin (BCG) immunization confers broad heterologous pro-
tection after vaccination. Thereby, BCG could potentially offer 
directly available protection in case of an outbreak, independent 
of the type of influenza virus outbreak.
Bacillus Calmette–Guérin, the widely used live attenuated 
vaccine against tuberculosis, has long been known for its immune 
modulatory effects. Upon its introduction in Sweden in 1932, 
the Swedish physician Carl Näslund observed a strong decrease 
in childhood mortality in the first year of life in the provinces 
in which BCG was introduced (9). This improvement could 
not be explained by prevention of tuberculosis alone. Similar 
observations were made several times upon introduction of BCG 
vaccination in other countries and were validated in randomized 
controlled trials (10, 11). Non-specific beneficial effects after BCG 
immunization have been demonstrated in several mouse studies, 
such as Plasmodium (12–14), Schistosoma (15), and disseminated 
Candida infection models (16). Moreover, it has been shown that 
BCG administration improves the outcome of a lethal challenge 
with the seasonal influenza A/Puerto Rico/8/34 (H1N1) in an 
experimental mouse model (17). The heterologous protective 
effects of BCG vaccination are at least partially explained by the 
induction of trained immunity: monocytes of BCG-vaccinated 
individuals display increased immune responsiveness, such as 
enhanced cytokine production upon restimulation with unre-
lated pathogens and toll-like receptor (TLR) ligands, a process 
which is dependent on epigenetic and metabolic rewiring of 
myeloid cells (16, 18). In epidemiological studies, the non-
specific effects of BCG vaccination are most pronounced in the 
first year of life, suggesting that trained immunity is most strongly 
activated during this first year (10, 19). This is in line with the 
study by Kleinnijenhuis et al. showing 1-year duration for trained 
immunity (20). Moreover, BCG vaccination resulted in hetero-
logous T-helper cell 1 (Th1) and T-helper cell 17 (Th17) immune 
responses and enhanced immunogenicity after subsequent influ-
enza vaccination in healthy volunteers (20, 21). Recently, we have 
shown that BCG vaccination resulted in reduced peak viremia 
after subsequent yellow fever vaccination of healthy volunteers, 
a process depending on the induction on monocyte responses, 
rather than T-cell heterologous immunity (22).
We therefore hypothesized that BCG vaccination may induce 
non-specific protection against influenza A (H7N9) infection, 
a strategy that may offer important public health benefits. In 
this study, we assessed the effects of BCG immunization in an 
expe rimental lethal avian influenza A/Anhui/1/2013 (H7N9) 
infection in BALB/c mice.
MaTerials anD MeThODs
h7n9 influenza Virus stock Preparation 
and TciD50 Determination
A/Anhui/1/2013 (H7N9) seed virus was obtained from the National 
Institute for Biological Standards and Control (UK). A new 
influenza A/Anhui/1/2013 (H7N9) virus stock was obtained after 
propagation in 11-day-old embryonic chicken eggs for 32  h at 
37°C. Aliquots were stored at <−70°C and were confirmed to be 
negative for endotoxin and mycoplasma. No novel mutations were 
introduced in the hemagglutinin and neuraminidase segments. 
The homology compared to the reference amino acid sequence 
(GenBank) was >99%. For the 50% tissue culture infectious dose 
(TCID50) assay, Madin–Darby Canine Kidney (MDCK) cells 
(ATCC CCL-34) were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM) (Gibco, Life technologies) with Glutamax 
(Gibco, Life technologies), 10% fetal calf serum (FCS) (Lonza, 
Switzerland), supplemented with 100 U/ml penicillin, 100 µg/ml 
streptomycin (Gibco, Life technologies), and 1× non-essential 
amino acids (Gibco, Life technologies) at 5% CO2 and 37°C. 
One day prior to the start of the assay, 30,000 cells per well were 
seeded in 96-well flat-bottom plates (Corning) and incubated 
overnight (37°C, 5% CO2). The cells were washed and incubated 
with serial dilutions of the influenza virus in culture medium 
(DMEM +  glutamax, supplemented with 100  U/ml penicillin, 
100 µg/ml streptomycin, 0.0004% trypsin-EDTA). After 7 days 
of incubation at 34°C, wells were scored for the cytopathic effect 
(CPE). The TCID50 titer was calculated using the Reed–Muench 
method (23).
animal ethics statement
Animals experiments were performed in accordance with the 
guidelines of the European Communities (Directive 2010/63/EU) 
Abbreviations: BCG, bacillus Calmette–Guérin; DMEM, Dulbecco’s Modified 
Eagle Medium; ELISA, enzyme-linked immunosorbent assay; IL-6, interleukin-6; 
IL-10, interleukin-10; IFN, interferon; LPS, lipopolysaccharide; MLD, mouse 
lethal dose; NP, nucleoprotein; PBMC, peripheral blood mononuclear cell; PHA, 
phytohemagglutin; RPMI, Roswell Park Memorial Institute; TCID, tissue culture 
infective dose; Th1, T-helper cell 1; Th17, T-helper cell 17; TLR, toll-like receptor; 
TNF-α, tumor necrosis factor-alpha.
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and Dutch legislation (The experiments on Animals Act, 1997). 
The animal experimental protocols were approved by an inde-
pendent Animal Ethics Committee (TNO, Zeist, the Netherlands) 
under project license 3387 and performed in the AAALAC acc-
redited animal facility of Triskelion. All animals were housed in 
a temperature and light-cycle controlled facility with unlimited 
access to food and water. All procedures involving live H7N9 
viruses, including the animal experiments, were carried out in a 
biosafety level 3 (BSL-3) containment facility at Triskelion. The 
animals were monitored for clinical signs of influenza disease 
twice daily with intervals of at least 5 h. All observations, includ-
ing behavioral aspects were recorded. If lethargy was observed 
longer than 48 h, the animal was euthanized (humane endpoint).
influenza challenge Model
Female BALB/cAnNCrl (BALB/c) mice were obtained (Charles 
River, Germany) and maintained under SPF conditions. At com-
mencement of the experiments, animals were 6–8  weeks old. 
All experiments were performed with 8–10 mice per group. On 
day 0, mice were challenged intranasally (i.n.) with influenza A/
Anhui/1/2013 (H7N9) diluted in 50 µl phosphate buffered saline 
(PBS) under anesthesia with ketamine/xylazine (50 and 5 mg/kg, 
respectively). To determine the 50% mouse lethal dose (MLD50), 
six groups of eight animals were challenged with 7.31, 6.17, 5.02, 
3.87, 2.73, or 1.58 log10 TCID50 per mouse and monitored until 
they succumbed to infection or until scheduled sacrifice 14 days 
post-infection. The MLD50 was calculated using the Spearman–
Kärber method. Throughout the experiment, clinical signs were 
monitored twice daily and body weight was recorded once daily 
until death or scheduled sacrifice.
As a reference control for the lethal challenge model, two addi-
tional groups received the neuraminidase inhibitor oseltamivir 
phosphate (Tamiflu®; Roche, Switzerland) dissolved in sterile 
water (Fresenius Kabi, the Netherlands) and stored at 2–10°C 
until use. One group of animals was treated with 100 mg/kg twice 
daily per os (p.o.) starting 1  h prior to the challenge on day 0 
continuing until day 4, while another group received oseltamivir 
on days 1–5. The control group was treated with vehicle PBS 
(Gibco, Life technologies) p.o. on days 0–4. For evaluation of the 
effect of BCG, animals received either 750 µg BCG (Danish strain 
1331; Statens Serum Institut, Denmark) dissolved in 200 µl PBS 
intravenously (i.v.), containing 2–8 × 106 colony-forming units, 
or PBS i.v. on day –7. To demonstrate induction of trained innate 
immune responses after BCG vaccination, five animals per group 
were sacrificed prior to the influenza challenge on day 0, after 
which splenocytes and peritoneal macrophages were isolated for 
ex vivo restimulation experiments. On day 0, the animals were 
challenged with a 4MLD50 dose influenza A/Anhui/1/2013 (H7N9) 
and monitored until they succumbed to infection or until sche-
duled sacrifice at 21  days post-infection. Three days after viral 
challenge, eight animals per group were sacrificed, and lungs 
were collected and prepared for histopathological analysis.
Ex Vivo stimulations of splenocytes  
and Peritoneal Macrophages
Spleen cells were isolated by gently squeezing spleens in a 
sterile 200  µM filter chamber. After washing with sterile PBS 
(1,200 rpm, 5 min, 4°C), cells were resuspended in 4 ml Roswell 
Park Memorial Institute (RPMI) 1640 culture medium (RPMI 
medium; Invitrogen, CA, USA) supplemented with 10% FCS. 
Cells were counted and concentrations were adjusted to 1 × 107 
cells/ml. Cells were cultured in 24-well plates (Greiner, the 
Netherlands) at 5 × 106 cells/well, in a final volume of 1,000 µl and 
stimulated in duplo with RPMI, Escherichia coli lipopolysaccha-
ride (LPS) (10 ng/ml, Sigma-Aldrich), phytohemagglutin (PHA) 
(10  µg/ml from Phaseolus vulgaris, Sigma-Aldrich). Poly I:C 
(50  µg/ml, Invi vogen), heat-killed Candida albicans (1  ×  106 
microorganisms/ml, strain UC820), heat-killed Salmonella typhi 
(1  ×  107 microorganisms/ml), or heat-killed Staphylococcus 
aureus (1 × 107 microorganisms/ml). After 2 days of incubation, 
500 µl supernatant was collected and the plates were incubated 
for another 3 days before the remaining supernatants were har- 
vested. The supernatants were stored at –80°C until levels of 
tumor necrosis factor-alpha (TNF-α), interferon (IFN)-α, IFN-γ, 
interleukin (IL)-17, and IL-22 were determined.
Peritoneal macrophages were isolated by injecting 5  ml of 
ice-cold sterile PBS in the peritoneal cavity. After centrifugation 
and washing, cells were resuspended in RPMI supplemented with 
10 µg/ml gentamicin, 10 mM Glutamax, and 10 mM pyruvate. 
Cells were counted using a Z1 Coulter Particle Counter (Beckman 
Coulter, the Netherlands) and adjusted to 1  ×  106 cells/ml. 
Cells were cultured in 96-well round-bottom microtiter plates 
(Costar, Corning, the Netherlands) at 1 × 105 cells/well, in a final 
volume of 200 µl. After 24 h of incubation with abovementioned 
stimuli in duplo {plus Pam3Cys [10 µg/ml, EMC microcollections 
(L2000)] instead of PHA} at 37°C in air and 5% CO2, the plates 
were centrifuged at 1,400 × g for 8 min, and the supernatants were 
collected and stored at –20°C until levels of TNF-α, IL-1α, IL-1β, 
IL-6, and IL-10 were determined.
Quantification of cytokine concentrations
Cytokine concentrations were determined in supernatants using 
commercial enzyme-linked immunosorbent assay (ELISA) kits 
according to instructions of the manufacturer. TNF-α (R&D 
systems, MN, USA), IL-1α, IL-1β, IL-6, IL-10, IFN-α, and IFN-γ 
(Sanquin, the Netherlands) were determined in supernatants 
harvested after 2 days of culture. IL-17 and IL-22 (R&D systems) 
were determined in supernatants after 5 days of incubation.
histopathology and 
immunohistochemistry
For histopathological examination, the lungs of both BCG and 
PBS treated animal groups were isolated 3 days post-challenge. 
Formalin fixed lung tissues were embedded in paraffin wax, sec- 
tioned at 4  µm, and stained with hematoxylin and eosin. Per 
animal, three consecutive HE-stained lung sections were semi-
quantitatively scored for the presence of signs of inflammation, 
epithelial damage, and repair. Influenza nucleoprotein (NP) was 
visualized by immunohistochemistry using anti-influenza A NP 
antibody (Millipore, clone H16-L10-4R5, mouse IgG2a) as a mea-
sure for the amount of virus present in cells in the lung according 
to the protocol described in Rimmelzwaan et al. (24). NP-stained 
sections were semi-quantitatively scored for the presence of viral 
FigUre 1 | Virulence of influenza A/Anhui/1/2013 (H7N9) in BALB/c mice. 
Female BALB/c mice (n = 8 per group) were intranasally inoculated with 
serial dilutions of the A/Anhui/1/2013 (H7N9) influenza virus on day 0 and 
survival was monitored for 14 days. Kaplan–Meyer survival curve (a) and 
mean body weight change is depicted (B). The MLD50 was calculated using 
the Reed–Muench method.
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protein. All parameters were scored as absent (0), minimal (1), 
moderate (2), or marked (3).
statistical analysis
Data were analyzed using Graphpad Prism 5.0 (La Jolla, CA, 
USA). *p-Value < 0.05, **p-value < 0.01. Cytokine data are shown 
as mean ± SEM. The survival proportion at day 21 after treat-
ment was compared to the vehicle control group using a Fisher 
exact two-sided test, corrected for multiple comparisons. Survi- 
val times after viral challenge of the groups were compared using 
a log-rank test. Change in body weight was summarized as area 
under the curve (AUC) in which the last observed body weight 
was carried forward if a mouse died/was euthanized during the 
study. Briefly, the weight per mouse at day 0 was used as baseline 
and weight change was determined relative to baseline. The AUCs 
for each group were summarized as mean, SD, and adjusted 
p-value for comparison to the vehicle control group.
resUlTs
Determination of Tissue culture infective 
Dose (TciD) and 50% MlD
Based on the CPE observed in the MDCK cells incubated with 
the dose formulation of A/Anhui/1/2013 (H7N9), a TCID50 of 
6.11 log10 TCID50/ml was calculated (data not shown). To assess 
the potency of BCG vaccination in vivo, we established a lethal 
A/Anhui/1/2013 (H7N9) influenza challenge model in female 
BALB/c mice, by inoculating groups of mice i.n. with a dose of 
7.31, 6.17, 5.02, 3.87, 2.73, or 1.58 log10 TCID50/mouse. During 
the subsequent MLD experiment, progress of infection the body 
weights correlated with an increase in the number and severity 
of the clinical signs. Recovery of the animals was demonstrated 
by an increase in body weight and a decrease in clinical signs. 
Intranasal administration of influenza A/Anhui/1/2013 (H7N9) 
was lethal to female (BALB/c) mice, which has been shown 
previously (25). The MLD50 determined for the A/Anhui/1/2013 
(H7N9) influenza was calculated at 4.45 log10 TCID50. The infec-
tious dose for the subsequent experimental challenge infection 
study was set at 4MLD50, a dose where 0–10% of the animals 
were expected to survive the intranasal challenge with the virus 
(Figures 1A,B).
assessment of Oseltamivir sensitivity  
of a/anhui/1/2013 (h7n9) challenge Model
To determine the sensitivity of the challenge model, we tested 
the efficacy of the most widely used anti-influenza virus drug, 
the neuraminidase inhibitor oseltamivir phosphate, as a refer-
ence control. Animals were challenged with an intranasal dose of 
4MLD50 influenza A/Anhui/1/2013 (H7N9). The control group 
(n = 10) was treated with PBS twice daily p.o. for 5 days, starting 
from day 0. Eight animals were treated twice daily with 100 mg/kg 
oseltamivir p.o. for 5 days, starting 1 h before challenge at day 0. 
Another eight mice started on day 1 with 100 mg/kg oseltami-
vir treatment twice daily for the duration of 5 days. Figure 2A 
presents the Kaplan–Meier survival curve. In the animals of the 
vehicle control group, 10% survival was observed after influenza 
A/Anhui/1/2013 (H7N9) challenge. Treatment with 100 mg/kg 
oseltamivir twice daily p.o. from day 0 to day 4 resulted in 100% 
survival, which was significantly improved compared to the vehi-
cle control group (p-value <  0.01) (Table S1 in Supplementary 
Material). Although treatment with 100  mg/kg oseltamivir 
twice daily p.o. from day 1 to day 5 also resulted in an increased 
survival proportion of 25%, this was not statistically different 
from the control group (Table S2 in Supplementary Material). 
Nevertheless, survival time was significantly increased in both 
oseltamivir treated groups (treatment day 0–4 p-value <  0.01, 
treatment day 1–5 p-value < 0.05) (Table S2 in Supplementary 
Material). Oseltamivir treatment starting from day 0 showed a 
significantly reduced body weight loss compared to the control 
group (p-value <  0.001), while initiating oseltamivir treatment 
1 day post-challenge, did not reduce the body weight loss com-
pared to the control group (Figure 2B; Table S3 in Supplementary 
Material).
Bcg Vaccination Prior to h7n9 infection 
challenge
To test the effect of BCG against lethal influenza challenge, a total 
of 13 mice were BCG immunized and 13 mice were injected with 
PBS 1 week prior to A/Anhui/1/2013 (H7N9) challenge.
FigUre 2 | Efficacy of oseltamivir in a lethal BALB/c mouse model. Female 
BALB/c mice were challenged with a dose of 4MLD50 influenza A/
Anhui/1/2013 (H7N9) on day 0. Mice received 100 mg/kg twice daily p.o. 
Oseltamivir treatment from days 0–4 or 1–5 (n = 8 per group) or the vehicle 
control (n = 10) from days 0–4. Kaplan–Meyer survival curve (a) and mean 
body weight change (B) are depicted. Survival proportion in the oseltamivir 
treated groups was analyzed using a Fisher’s exact two-sided test with 
Bonferroni correction for multiple comparisons. The effect of oseltamivir 
treatment on body weight was analyzed by comparing the area under curve 
of treatment groups with vehicle and was analyzed using a two-way ANOVA 
with Bonferroni correction. Error bars depict SEM. ****p < 0.001, 
****p < 0.0001.
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cytokine responses after Ex Vivo 
splenocyte and Peritoneal  
Macrophage restimulation
To assess the systemic trained immunity responses, splenocytes 
as well as peritoneal macrophages (5 mice per group) were iso-
lated 7 days after BCG immunization. Both cell suspensions were 
restimulated with several TLR-ligands and pathogens. Cytokines 
were determined by ELISA in collected supernatants. TNF-α pro-
duction was significantly increased in the BCG-vaccinated group 
after restimulation of splenocytes with all stimuli except RPMI 
medium control (p-value <  0.01 for all stimuli) (Figure  3A). 
Splenocyte-derived IFN-γ responses were significantly upregu-
lated after LPS (p-value < 0.01), C. albicans (p-value < 0.05), and 
S. typhi (p-value < 0.05) restimulation (Figure 3B). No significant 
differences were found on splenocyte-derived IL-17 and IL-22 
responses (Figures 3C,E). IFN-α was only determined in super-
natants of splenocytes restimulated with RPMI and poly I:C. 
Restimulation with poly I:C resulted in a small but statistically 
significantly higher IFN-α response in the BCG-vaccinated group 
(p-value <  0.05) (Figure 3D). Significantly higher TNF-α pro-
duction in the BCG-immunized mice was found when peritoneal 
macrophages were restimulated with S. typhi (p-value < 0.05) and 
S. aureus (p-value < 0.05) (Figure 3F). Although a consistent trend 
in increased IL-6 production was observed when peritoneal mac-
rophages of the BCG-vaccinated group were restimulated with 
all pathogens and TLR ligands, only stimulation with C. albicans 
resulted in a statistically significant increase in comparison to the 
control group (p-value < 0.05) (Figure 3G). IL-1α, IL-1β, and IL-10 
responses (Figures 3H–J) did not differ between groups.
Bcg Vaccination Does not Protect Mice 
During h7n9 influenza infection
No survival (0%) was observed in the animals of vehicle control 
group 11 days after A/Anhui/1/2013 (H7N9) challenge. Despite 
the heterologous induction of trained immunity responses, as 
reported above, vaccination with BCG did not result in a statisti-
cally significant improvement in survival proportion compared 
to the vehicle control group (12.5% survival in BCG treated 
group) (Table S1 in Supplementary Material). Furthermore, 
BCG vaccination did not result in a statistically significant 
improvement in survival time compared to the vehicle control 
group (p-value = 0.82) (Figure 4A; Table S2 in Supplementary 
Material). The percentage body weight change per animal was 
determined relative to day 0. Similar to the vehicle control group, 
all animals in the BCG-vaccinated displayed a steep reduction in 
bodyweight starting from day 1 until day 11. The single surviving 
animal in the BCG-treated group started to recover after day 11. 
BCG vaccination did not result in a significant difference in body 
weight loss compared to the vehicle control group (p-value = 0.15) 
(Figure  4B; Table S3 in Supplementary Material). From day 0 
onward, the severity of influenza infection was graded as a clinical 
score based on the observation of one or multiple clinical signs 
typical for influenza infection. The mean clinical scores did not 
differ between the vehicle control group and BCG-immunized 
group (Figure S1 in Supplementary Material).
Bcg Vaccination Does not reduce 
histopathological Damage, inflammation, 
or Viral replication
Three days after challenge infection, histopathological lung exa-
mination was performed in a subgroup of both vehicle control 
and BCG-vaccinated mice. The pathological changes observed 
in the lungs isolated from these mice corresponded with acute 
lung injury, characterized by epithelial necrosis and infiltration 
of macrophages, lymphocytes, and granulocytes (Figures 5A,B). 
In addition, squamous metaplasia was observed. No differences 
in pathological changes between the lungs of the BCG vaccinated 
and vehicle control mice were observed at day 3 after challenge 
infection (Figures 5C,D). Histological scores for the amount of 
granulocytes, macrophages, and lymphocytes were similar bet- 
ween the BCG immunized and control group (Figure  5E). 
Although BCG did not have an effect on pulmonary tissue inflam-
mation or immune cell composition, we wanted to determine 
FigUre 3 | Bacillus Calmette–Guérin (BCG)-induced trained immunity cytokine responses. To demonstrate increased innate immune response after BCG 
vaccination, spleen cells and peritoneal macrophages were isolated 7 days after administration of either BCG or phosphate buffered saline. Concentrations of tumor 
necrosis factor-alpha (TNF-α), interferon (IFN)-α, IFN-γ, interleukin (IL)-17, and IL-22 determined by enzyme-linked immunosorbent assay (ELISA) in supernatants of 
restimulated splenocytes with Roswell Park Memorial Institute (RPMI), lipopolysaccharide (LPS), phytohemagglutin (PHA), poly I:C, Candida albicans, Salmonella 
typhi, and Staphylococcus aureus are shown (a–e). Concentrations of IL-1α, IL-1β, IL-6, IL-10, and TNF-α determined by ELISA in supernatants of restimulated 
peritoneal macrophages with RPMI, LPS, poly I:C, C. albicans, S. typhi, and S. aureus are shown (F–J). Data are shown as mean ± SEM, n = 5 per group, 
*p < 0.05, **p < 0.01 Mann–Whitney U (two-sided).
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the effect of BCG immunization on local influenza infection and 
replication (by scoring of influenza infected cells). Lung tissue 
sections slides were stained with influenza NP to determine the 
quantity of influenza virions (Figures 6A,B). The scores of NP 
stained small bronchi, large bronchi, or alveoli did not differ 
between groups (Figure 6C). This indicates that intravenous BCG 
FigUre 4 | Bacillus Calmette–Guérin (BCG) vaccination does not protect 
mice during H7N9 influenza infection. Female BALB/c mice were challenged 
with a dose of 4MLD50 influenza A/Anhui/1/2013 (H7N9) on day 0. Mice 
received 750 µg BCG or the vehicle control (phosphate buffered saline) i.v. on 
day −7. Kaplan–Meyer survival curve (a) and mean body weight change  
(B) are depicted. Survival proportion in the BCG treated group was statistically 
analyzed using a Fisher’s exact two-sided test. Survival time was statistically 
analyzed using a Mantel and Cox log-rank test. The effect of BCG treatment 
on body weight was analyzed by comparing the area under curve of treatment 
groups with vehicle and was statistically analyzed using a two-way ANOVA 
with Bonferroni correction. Data are shown as mean ± SEM, n = 8 per group.
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administration did not reduce influenza A (H7N9) infection or 
replication in mice.
DiscUssiOn
The avian influenza A (H7N9) virus appears to have become more 
virulent during recent epidemics in China, underlining the risk of 
a global human pandemic in the absence of specific immunity. In 
case of an outbreak in the absence of available specific vaccines, 
BCG might contribute to control of avian influenza through its 
non-specific protective effects, which are probably related to its 
capacity to induce trained immunity in monocytes. In this study, 
we tested the effect of intravenous BCG against a lethal influenza 
A/Anhui/1/2013 (H7N9) infection in mice.
We were able to reproduce previous findings regarding induc-
tion of systemic trained immunity after BCG administration in 
mice (16). Intravenous BCG immunization resulted in signifi-
cantly increased cytokine responses upon ex vivo restimulation 
with unrelated TLR-ligands and pathogens, both in splenocytes 
(TNF-α, IFN-α, and IFN-γ) and peritoneal macrophage (TNF-α 
and IL-6). However, increased ex vivo cytokine production was 
not associated with differences in experimental avian influenza 
A/Anhui/1/2013 (H7N9) infection in terms of survival, clinical 
scores, or pulmonary inflammation.
A recent study demonstrated that low dose BCG (TICE 
strain) administration protects against mouse-adapted influenza 
virus A/Puerto Rico/8/34 (PR8) (H1N1) strain by increased 
efferocytosis of alveolar phagocytes, but only after i.n. and not 
after subcutaneously administration of BCG (26). Similar obser-
vations were reported previously; i.n. BCG (strain unspecified) 
immunized mice showed enhanced protection against influenza 
A (H1N1) PR8 challenge compared to intraperitoneally immu-
nized mice (17). This suggests the route of BCG administration 
might be important in case of protection against influenza. In 
the study of Mukherjee et al. (26), mice were inoculated with a 
lower dose of BCG compared to the administered dose in our 
study, pointing out that not only the route of administration but 
maybe also the dose and inherent dose-dependent kinetics might 
be crucial for heterologous protection. For several TLR-ligands, 
it has been shown that the dose during initial priming determines 
if monocytes will either become trained or tolerized during the 
in vitro trained immunity model (27). One could hypothesize that 
induction of either training or tolerance may be different per cell 
and tissue type as well. Although in vivo dose response studies of 
BCG priming in the context of trained immunity have not been 
performed yet, these in vitro data indicate the initial dose might 
be discriminative between being protective or not. That being 
said, a similar dose, route of administration as well as BCG strain 
were nevertheless protective against a lethal C. albicans challenge 
infection in severe combined immunodeficient mice, resulting 
in enhanced survival, decreased kidney yeast burden, and ex 
vivo trained immunity responses (16). This may suggest that the 
beneficial effects of BCG vaccination have specificity, and thus 
induce protection against some, but not all, infections.
As reviewed by Kuiken et al. (28), the innate immune system 
plays an important role in the first line defense against influenza 
infections. Influenza recognition by TLR and RIG-1 signaling 
leads to production of pro-inflammatory cytokines and type I 
IFNs. Especially type I IFNs are known to exert antiviral acti-
vity. Nevertheless, an imbalanced cytokine response or so-called 
cytokine storm could be detrimental for the host. Compared to 
seasonal strains, severe infections with highly pathogenic H5N1 
and 1918 H1N1 are more frequently associated with a dysregu-
lated cytokine response (29, 30). Likewise, severe cases of H7N9 
infections are complicated by hypercytokinemia (3, 31, 32). 
In the study of Mukherjee et  al., intranasal BCG inoculation 
resulted in decreased TNF-α mRNA and increased IL-10 mRNA 
expression in alveolar macrophages 2  days post PR8 (H1N1) 
infection (26). We did not study the local pulmonary mucosal 
cytokine responses after intravenous administration of BCG, but 
our findings regarding cytokine responses of ex vivo restimulated 
splenocytes and peritoneal macrophages are pointing toward 
priming in a different direction, with potentiation of cytokine 
responses. Future studies should focus on the role of alternative 
cell types like alveolar macrophages.
One unavoidable limitation for the conclusions of this study 
is that it investigated the effect of BCG vaccination in mice. 
FigUre 5 | Bacillus Calmette–Guérin (BCG) vaccination does not lead to reduction of histopathological damage and inflammation. Female BALB/c mice were 
challenged with a dose of 4MLD50 influenza A/Anhui/1/2013 (H7N9) on day 0. Mice received 750 µg BCG or vehicle control (phosphate buffered saline) i.v. on day 
–7 (n = 8 per group). Three days after viral challenge, lungs were fixed in formalin. Paraffin-embedded tissue sections were then stained for hematoxylin and eosin. 
Representative histopathological image of vehicle versus BCG-treated mice are depicted (a,B). Lung sections were scored from absent to marked: score “0” 
(absent), score “1” (minimal), score “2” (moderate), and score “3” (marked) for epithelial necrosis (damage) (c), inflammation markers (D), and inflammatory cell 
types (e). Results were statistically analyzed using the Cochran–Mantel–Haenszel test. Data are shown as mean ± SEM.
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Anti-mycobacterial as well as anti-influenza responses are differ-
ent in mice and humans, and it is conceivable to hypothesize that 
BCG vaccination may exert stronger beneficial effects in humans, 
including against influenza infection. Recently, we have shown 
that BCG vaccination in healthy human volunteers protects 
against experimental yellow fever vaccine viremia, while the 
protective serological response retains intact (22). The absence 
of IL-1β upregulation after BCG vaccination by splenocytes and 
peritoneal macrophages in the current study can be explained by 
the differences between the human and murine immunological 
responses. Humans have an increased IL-1β response compared 
to mice and mice lack important regulators of the IL-1 pathway 
such as IL-37 (33).
Another limitation of the study is represented by the particu-
larities of the BCG vaccination in mice, compared to humans. 
Earlier studies done in mice have shown that systemic trained 
immunity by BCG is induced after intravenous administration, 
rather than intradermal administration (34). In line with this, an 
earlier study by Spencer et al. showed protection against influenza 
A (H1N1) infection after intraperitoneal vaccination with BCG, 
indicating that systemic administration of BCG was protective 
against influenza (17). Furthermore, the administered dose of 
BCG the animals received and the timing of 7 days before the 
experimental avian influenza A/Anhui/1/2013 (H7N9) infection 
were equivalent to our previous intravenous BCG vaccination 
experimental protocols and comparable to the intraperitoneal 
BCG vaccination of mice (16–18). We hypothesized that in BCG-
vaccinated mice, the infiltration of trained immune cells in the 
lungs during the experimental avian influenza A/Anhui/1/2013 
(H7N9) infection would result in increased clearance of the 
FigUre 6 | Nucleoprotein (NP) staining of bronchi and alveoli indicates that bacillus Calmette–Guérin (BCG) does not reduce influenza virus replication. Female 
BALB/c mice were challenged with a dose of 4MLD50 influenza A/Anhui/1/2013 (H7N9) on day 0. Mice received 750 µg BCG or the vehicle control (phosphate 
buffered saline) i.v. on day –7 (n = 8 per group). Three days after viral challenge, lungs were fixed in formalin. Paraffin-embedded tissue sections were then stained 
for influenza NP. Representative images of influenza A NP-stained lungs of mice treated with vehicle versus BCG-treated mice are depicted (a,B). NP-staining was 
scored from absent to 3: score “0” (absent), score “1” (minimal), score “2” (moderate), and score “3” (marked) (c). Results were statistically analyzed using the 
Cochran–Mantel–Haenszel test. Data are shown as mean ± SEM. 
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influenza infection. While our data clearly demonstrate that this 
BCG vaccination model does not protect against H7N9 influenza 
infection, we cannot exclude that the different route of BCG 
administration in humans may have an effect.
Partial protection of BCG vaccination has been observed in 
a human-controlled malaria infection model as well, in which 
decreased parasitemia correlated with accelerated immune acti - 
vation and trained immunity in vivo upon blood stage parasitemia 
(Walk, de Bree et  al., submitted). A previous randomized con-
trolled trial has shown BCG vaccination prior to trivalent influ-
enza vaccination resulted in enhanced immunogenicity of the 
influenza vaccine, resulting in increased antibody response and 
seroconversion against the 2009 pandemic influenza A (H1N1) 
strain (21). Future studies should explore if BCG could function 
as an adjuvant to avian influenza vaccines as well.
In conclusion, intravenous administration of BCG enabled 
the induction of trained immunity, but this was not protective in 
a lethal influenza A/Anhui/1/2013 (H7N9) challenge infection 
in BALB/c mice. Future studies are needed to evaluate the anti-
influenza effects of BCG vaccination in humans.
eThics sTaTeMenT
Animals experiments were performed in accordance with the 
guidelines of the European Communities (Directive 2010/63/EU) 
and Dutch legislation (The experiments on Animals Act, 1997). 
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The animal experimental protocols were approved by an indepen-
dent Animal Ethics Committee (TNO, Zeist, the Netherlands) under 
project license 3387 and performed in the AAALAC accredited ani-
mal facility of Triskelion. All animals were housed in a temperature 
and light-cycle controlled facility with unlimited access to food and 
water. All procedures involving live H7N9 viruses, including the 
animal experiments, were carried out in a BSL-3 containment facility 
at Triskelion. The animals were monitored for clinical signs of influ-
enza disease twice daily with intervals of at least 5 h. All observations, 
including behavioral aspects were recorded. If lethargy was observed 
longer than 48 h, the animal was euthanized (humane endpoint).
aUThOr cOnTriBUTiOns
Participated in research design: RM, JD, MN, and LJ. Conducted 
experiments: RM and JK. Performed data analysis: RM, SH, MW, 
and CLCJdB. Wrote the manuscript: CLCJdB and RM. Critically 
read the manuscript: PA, RC, CSB, DD, JD, MW, MN, LJ, SH, 
and JK.
acKnOWleDgMenTs
MN was supported by an ERC Consolidator Grant (#310372) and 
a Spinoza Grant of the Netherlands Organization for Scientific 
Research. CSB and PA were supported by the Danish National 
Research Foundation (DNRF108).
sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found online at 
https://www.frontiersin.org/articles/10.3389/fimmu.2018.00869/
full#supplementary-material.
reFerences
1. WHO. Influenza at the Human-Animal Interface. (2017). Summary and 
assessment, 30 October to 7 December 2017. Available  from: http://www.
who.int/influenza/human_animal_interface/Influenza_Summary_IRA_HA_
interface_12_07_2017.pdf 
2. Wang X, Jiang H, Wu P, Uyeki TM, Feng L, Lai S, et al. Epidemiology of avian 
influenza A H7N9 virus in human beings across five epidemics in mainland 
China, 2013-17: an epidemiological study of laboratory-confirmed case series. 
Lancet Infect Dis (2017) 17(8):822–32. doi:10.1016/S1473-3099(17)30323-7 
3. Chen Y, Liang W, Yang S, Wu N, Gao H, Sheng J, et al. Human infections with the 
emerging avian influenza A H7N9 virus from wet market poultry: clinical anal-
ysis and characterisation of viral genome. Lancet (2013) 381(9881):1916–25. 
doi:10.1016/S0140-6736(13)60903-4 
4. Cox RJ, Madhun AS, Hauge S, Sjursen H, Major D, Kuhne M, et al. A phase I 
clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine  
(2009) 27(13):1889–97. doi:10.1016/j.vaccine.2009.01.116 
5. Couch RB, Patel SM, Wade-Bowers CL, Nino D. A randomized clinical 
trial of an inactivated avian influenza A (H7N7) vaccine. PLoS One (2012) 
7(12):e49704. doi:10.1371/journal.pone.0049704 
6. Mulligan MJ, Bernstein DI, Winokur P, Rupp R, Anderson E, Rouphael N, 
et al. Serological responses to an avian influenza A/H7N9 vaccine mixed at 
the point-of-use with MF59 adjuvant: a randomized clinical trial. JAMA 
(2014) 312(14):1409–19. doi:10.1001/jama.2014.12854 
7. Madan A, Segall N, Ferguson M, Frenette L, Kroll R, Friel D, et  al. 
Immunogenicity and safety of an AS03-adjuvanted H7N9 pandemic influ- 
enza vaccine in a randomized trial in healthy adults. J Infect Dis (2016) 
214(11):1717–27. doi:10.1093/infdis/jiw414 
8. Jackson LA, Campbell JD, Frey SE, Edwards KM, Keitel WA, Kotloff KL, 
et al. Effect of varying doses of a monovalent H7N9 influenza vaccine with 
and without AS03 and MF59 adjuvants on immune response: a randomized 
clinical trial. JAMA (2015) 314(3):237–46. doi:10.1001/jama.2015.7916 
9. Näslund C. Resultats des experiences de vaccination par le BCG poursuivies dans le 
Norrbotten (Suède) (Septembre 1927–Décembre 1931). Vaccination Preventative 
de Tuberculose, Rapports et Documents. Paris: Institut Pasteur (1932).
10. Aaby P, Roth A, Ravn H, Napirna BM, Rodrigues A, Lisse IM, et  al.  
Randomized trial of BCG vaccination at birth to low-birth-weight children: 
beneficial nonspecific effects in the neonatal period? J Infect Dis (2011) 
204(2):245–52. doi:10.1093/infdis/jir240 
11. Biering-Sorensen S, Aaby P, Napirna BM, Roth A, Ravn H, Rodrigues A, et al. 
Small randomized trial among low-birth-weight children receiving bacillus 
Calmette-Guerin vaccination at first health center contact. Pediatr Infect Dis J 
(2012) 31(3):306–8. doi:10.1097/INF.0b013e3182458289 
12. Parra M, Liu X, Derrick SC, Yang A, Tian J, Kolibab K, et  al. Molecular 
analysis of non-specific protection against murine malaria induced by 
BCG vaccination. PLoS One (2013) 8(7):e66115. doi:10.1371/journal.pone. 
0066115 
13. Matsumoto S, Yukitake H, Kanbara H, Yamada H, Kitamura A, Yamada T. 
Mycobacterium bovis bacillus Calmette-Guerin induces protective immu-
nity against infection by Plasmodium yoelii at blood-stage depending on 
shifting immunity toward Th1 type and inducing protective IgG2a after 
the parasite infection. Vaccine (2000) 19(7–8):779–87. doi:10.1016/S0264- 
410X(00)00257-7 
14. Clark IA, Allison AC, Cox FE. Protection of mice against Babesia and Plas-
modium with BCG. Nature (1976) 259(5541):309–11. doi:10.1038/259309a0 
15. Tribouley J, Tribouley-Duret J, Appriou M. [Effect of bacillus Callmette 
Guerin (BCG) on the receptivity of nude mice to Schistosoma mansoni]. C R 
Seances Soc Biol Fil (1978) 172(5):902–4. 
16. Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Ifrim DC, Saeed S, et al. 
Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection 
from reinfection via epigenetic reprogramming of monocytes. Proc Natl 
Acad Sci U S A (2012) 109(43):17537–42. doi:10.1073/pnas.1202870109 
17. Spencer JC, Ganguly R, Waldman RH. Nonspecific protection of mice 
against influenza virus infection by local or systemic immunization with 
bacille Calmette-Guerin. J Infect Dis (1977) 136(2):171–5. doi:10.1093/
infdis/136.2.171 
18. Arts RJ, Carvalho A, La Rocca C, Palma C, Rodrigues F, Silvestre R, et  al. 
Immunometabolic pathways in BCG-induced trained immunity. Cell Rep 
(2016) 17(10):2562–71. doi:10.1016/j.celrep.2016.11.011 
19. Benn CS, Netea MG, Selin LK, Aaby P. A small jab – a big effect: nonspe-
cific immunomodulation by vaccines. Trends Immunol (2013) 34(9):431–9. 
doi:10.1016/j.it.2013.04.004 
20. Kleinnijenhuis J, Quintin J, Preijers F, Benn CS, Joosten LA, Jacobs C, et al. 
Long-lasting effects of BCG vaccination on both heterologous Th1/Th17 
responses and innate trained immunity. J Innate Immun (2014) 6(2):152–8. 
doi:10.1159/000355628 
21. Leentjens J, Kox M, Stokman R, Gerretsen J, Diavatopoulos DA, van Crevel R, 
et  al. BCG vaccination enhances the immunogenicity of subsequent influ-
enza vaccination in healthy volunteers: a randomized, Placebo-Controlled 
Pilot Study. J Infect Dis (2015) 212(12):1930–8. doi:10.1093/infdis/jiv332 
22. Arts RJW, Moorlag S, Novakovic B, Li Y, Wang SY, Oosting M, et al. BCG 
vaccination protects against experimental viral infection in humans through 
the induction of cytokines associated with trained immunity. Cell Host 
Microbe (2018) 23(1):89.e–100.e. doi:10.1016/j.chom.2017.12.010 
23. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. 
Am J Trop Med Hyg (1938) 27(20):493–7. 
24. Rimmelzwaan GF, Kuiken T, van Amerongen G, Bestebroer TM, Fouchier RA, 
Osterhaus AD. Pathogenesis of influenza A (H5N1) virus infection in a 
primate model. J Virol (2001) 75(14):6687–91. doi:10.1128/JVI.75.14.6687- 
6691.2001 
11
de Bree et al. BCG Prior to H7N9 Challenge
Frontiers in Immunology | www.frontiersin.org April 2018 | Volume 9 | Article 869
25. Belser JA, Gustin KM, Pearce MB, Maines TR, Zeng H, Pappas C, et  al. 
Pathogenesis and transmission of avian influenza A (H7N9) virus in ferrets 
and mice. Nature (2013) 501(7468):556–9. doi:10.1038/nature12391 
26. Mukherjee S, Subramaniam R, Chen H, Smith A, Keshava S, Shams H. 
Boosting efferocytosis in alveolar space using BCG vaccine to protect host 
against influenza pneumonia. PLoS One (2017) 12(7):e0180143. doi:10.1371/
journal.pone.0180143 
27. Ifrim DC, Quintin J, Joosten LA, Jacobs C, Jansen T, Jacobs L, et al. Trained 
immunity or tolerance: opposing functional programs induced in human 
monocytes after engagement of various pattern recognition receptors. Clin 
Vaccine Immunol (2014) 21(4):534–45. doi:10.1128/CVI.00688-13 
28. Kuiken T, Riteau B, Fouchier RA, Rimmelzwaan GF. Pathogenesis of influ-
enza virus infections: the good, the bad and the ugly. Curr Opin Virol (2012) 
2(3):276–86. doi:10.1016/j.coviro.2012.02.013 
29. Short KR, Veeris R, Leijten LM, van den Brand JM, Jong VL, Stittelaar K, 
et  al. Proinflammatory cytokine responses in extra-respiratory tissues dur-
ing severe influenza. J Infect Dis (2017) 216(7):829–33. doi:10.1093/infdis/ 
jix281 
30. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, et al. 
Fatal outcome of human influenza A (H5N1) is associated with high viral 
load and hypercytokinemia. Nat Med (2006) 12(10):1203–7. doi:10.1038/ 
nm1477 
31. Zhou J, Guo X, Fang D, Yu Y, Si L, Wang Y, et al. Avian influenza A (H7N9) 
viruses isolated from patients with mild and fatal infection differ in patho-
genicity and induction of cytokines. Microb Pathog (2017) 111:402–9. 
doi:10.1016/j.micpath.2017.08.022 
32. Wang Z, Zhang A, Wan Y, Liu X, Qiu C, Xi X, et  al. Early hypercyto- 
kinemia is associated with interferon-induced transmembrane protein-3 
dysfunction and predictive of fatal H7N9 infection. Proc Natl Acad Sci U S A 
(2014) 111(2):769–74. doi:10.1073/pnas.1321748111 
33. Dinarello CA. Overview of the IL-1 family in innate inflammation and 
acqu ired immunity. Immunol Rev (2018) 281(1):8–27. doi:10.1111/imr. 
12621 
34. Kaufmann E, Sanz J, Dunn JL, Khan N, Mendonca LE, Pacis A, et al. BCG 
educates hematopoietic stem cells to generate protective innate immunity 
against tuberculosis. Cell (2018) 172(1–2):176–90.e19. doi:10.1016/j.cell. 
2017.12.031 
Conflict of Interest Statement: JD is currently employed by Aduro Biotech, but 
was employed by Triskelion when the studies were performed. All other authors 
declare no competing interests.
The reviewer CL and handling Editor declared their shared affiliation.
Copyright © 2018 de Bree, Marijnissen, Kel, Rosendahl Huber, Aaby, Benn, Wijnands, 
Diavatopoulos, van Crevel, Joosten, Netea and Dulos. This is an open-access article 
distributed under the terms of the Creative Commons Attribution License (CC 
BY). The use, distribution or reproduction in other forums is permitted, provided 
the original author(s) and the copyright owner are credited and that the original 
publication in this journal is cited, in accordance with accepted academic practice. No 
use, distribution or reproduction is permitted which does not comply with these terms.
